Instil Bio

TIL

ATLANTA, GA – – (ACCESSWIRE – November 7, 2022) – – Holzer & Holzer, LLC is investigating whether Instil Bio, Inc. (“Instil Bio” or the “Company”) (NASDAQ: TIL) complied with federal securities laws.  On October 31, 2022, Instil Bio announced a pause in enrollment in its ongoing clinical trials of ITIL-168 and ITIL-306 due to “a recent decrease in the rate of successful manufacturing of ITIL-168, resulting in the inability to dose some patients whose individual product of ITIL-168 was not successfully manufactured.”  Following this announcement, the Company’s stock price dropped.

 

If you purchased Instil Bio stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at  cholzer@holzerlaw.com  or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at https://holzerlaw.com/case/instil-bio/  to discuss your legal rights.

Registration Deadline

Lead Plaintiff Deadline Has Passed

Submit Your Information

Name(Required)
Address
MM slash DD slash YYYY
Shares Purchased(Required)
Number of Shares Acquired
Acquisition Price Per Share
 
MM slash DD slash YYYY
Shares Sold
Number of Shares Sold
Selling Price Per Share
 
By clicking on the button below, I am requesting Holzer & Holzer, LLC send me documents necessary to retain the firm.